$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2022 Q1 Form 10-K Financial Statement

#000109181822000014 Filed on February 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 2020 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $132.4K $502.0K $122.6K
YoY Change -8.73% -99.68% 507.68%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $132.4K $502.0K $122.6K
YoY Change -8.73% -99.68% 507.68%
Operating Profit -$132.4K -$502.0K -$122.6K
YoY Change -8.73% -99.68% 507.68%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$132.4K -$502.0K -$122.6K
YoY Change -8.73% -99.68% 507.68%
Income Tax
% Of Pretax Income
Net Earnings -$132.4K -$502.0K -$122.6K
YoY Change -8.73% -99.68% 507.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.523K -$17.15K -$640.0K
COMMON SHARES
Basic Shares Outstanding 29.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.11K $11.11K $39.87K
YoY Change -65.11% -72.13% -24.63%
Cash & Equivalents $11.11K $39.87K
Short-Term Investments
Other Short-Term Assets $10.00 $40.00 $0.00
YoY Change -91.67% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.12K $11.15K $39.87K
YoY Change -65.21% -72.03% -32.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $11.12K $11.15K $39.87K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $11.12K $11.15K $39.87K
YoY Change -65.21% -72.03% -32.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $6.310K
YoY Change -100.0% 23.97%
Accrued Expenses $856.3K $750.5K $327.5K
YoY Change 97.63% 129.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.005M $873.0K $399.8K
YoY Change 87.24% 118.38% 3349.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.005M $873.0K $399.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.005M $873.0K $399.8K
YoY Change 87.24% 118.38% 3349.29%
SHAREHOLDERS EQUITY
Retained Earnings -$159.2M
YoY Change
Common Stock $158.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$994.3K -$861.9K -$359.9K
YoY Change
Total Liabilities & Shareholders Equity $11.12K $11.15K $39.87K
YoY Change -65.21% -72.03% -32.32%

Cashflow Statement

Concept 2022 Q1 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$132.4K -$502.0K -$122.6K
YoY Change -8.73% -99.68% 507.68%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$32.94K -$77.77K -$11.15K
YoY Change 1.82% -3.02% 8.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.94K $49.01K 11.15K
YoY Change 35.44% -27.03% -31.3%
NET CHANGE
Cash From Operating Activities -32.94K -$77.77K -11.15K
Cash From Investing Activities 0.000
Cash From Financing Activities 32.94K $49.01K 11.15K
Net Change In Cash $0.00 -$28.76K 0.000
YoY Change 120.72% -100.0%
FREE CASH FLOW
Cash From Operating Activities -$32.94K -$77.77K -$11.15K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29271755 shares
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001310488
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity Registrant Name
EntityRegistrantName
BIOFORCE NANOSCIENCES HOLDINGS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity File Number
EntityFileNumber
000-51074
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-3078125
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2020 General Booth Blvd.
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 230
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Virginia Beach
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23454
CY2021 dei City Area Code
CityAreaCode
757
CY2021 dei Local Phone Number
LocalPhoneNumber
306-6090
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
8190333 USD
CY2021 dei Auditor Firm
AuditorFirmId
5041
CY2021 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2021 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11105 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
40 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11145 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
39865 USD
CY2021Q4 us-gaap Assets
Assets
11145 USD
CY2020Q4 us-gaap Assets
Assets
39865 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6313 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5090 USD
CY2021Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
750517 USD
CY2020Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
327517 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
116178 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
67166 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
873008 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
399773 USD
CY2021Q4 us-gaap Liabilities
Liabilities
873008 USD
CY2020Q4 us-gaap Liabilities
Liabilities
399773 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29272 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
29272 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159672262 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159170307 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-861863 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-359908 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11145 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39865 USD
CY2021 us-gaap Revenues
Revenues
USD
CY2020 us-gaap Revenues
Revenues
USD
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
USD
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
USD
CY2021 us-gaap Gross Profit
GrossProfit
USD
CY2020 us-gaap Gross Profit
GrossProfit
USD
CY2021 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
423000 USD
CY2020 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
158327517 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
81038 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-501955 USD
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29271755 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16304367 shares
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.72
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-501955 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-158408555 USD
CY2021 bfnh Common And Preferred Stock Issued For Current Year Board Of Directors Compensation
CommonAndPreferredStockIssuedForCurrentYearBoardOfDirectorsCompensation
USD
CY2020 bfnh Common And Preferred Stock Issued For Current Year Board Of Directors Compensation
CommonAndPreferredStockIssuedForCurrentYearBoardOfDirectorsCompensation
158000000 USD
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
40 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-6000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1223 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5158 USD
CY2021 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
423000 USD
CY2020 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
327517 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77772 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80196 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
49012 USD
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
67166 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49012 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67166 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28760 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13030 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52895 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11105 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1167 shares
CY2021 us-gaap Interest Paid Net
InterestPaidNet
USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
USD
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021 bfnh Common Stock Issued To Pay Stock Payable
CommonStockIssuedToPayStockPayable
USD
CY2020 bfnh Common Stock Issued To Pay Stock Payable
CommonStockIssuedToPayStockPayable
1339 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47308 USD
CY2020 bfnh Common Stock Issued To Pay Accounts Payable
CommonStockIssuedToPayAccountsPayable
1339 USD
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
158000000 USD
CY2020 bfnh Incremental Common Shares Value Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesValueAttributableToConversionOfPreferredStock
USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-158408555 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-861863 USD
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 USD
CY2020 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1339 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:12pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">Use of Estimates</span></p> <p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:12pt; margin-bottom:0pt; ">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.79
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares

Files In Submission

Name View Source Status
0001091818-22-000014-index-headers.html Edgar Link pending
0001091818-22-000014-index.html Edgar Link pending
0001091818-22-000014.txt Edgar Link pending
0001091818-22-000014-xbrl.zip Edgar Link pending
a0101450current001.jpg Edgar Link pending
a0101450current002.jpg Edgar Link pending
a0101450current003.jpg Edgar Link pending
bfnh-20211231.xsd Edgar Link pending
bfnh-20211231_cal.xml Edgar Link unprocessable
bfnh-20211231_def.xml Edgar Link unprocessable
bfnh-20211231_lab.xml Edgar Link unprocessable
bfnh-20211231_pre.xml Edgar Link unprocessable
bfnh10k1221.htm Edgar Link pending
bfnh10k1221_htm.xml Edgar Link completed
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex321.htm Edgar Link pending
ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending